Table 1.
Comparison of patient characteristics between the romosozumab and denosumab groups at baseline.
| Variables; median (Q1, Q3) | Romosozumab group (n = 25) | Denosumab group (n = 25) | P-value |
|---|---|---|---|
| Age, yr | 74 (70, 80) | 73 (68, 77) | 0.497 |
| Disease duration, yr | 10 (5, 16) | 11 (6, 17) | 0.606 |
| Height, cm | 151.5 (147, 156) | 152.0 (146.5, 154) | 0.711 |
| Body weight, kg | 47.9 (43, 54) | 51.4 (45, 54.6) | 0.593 |
| bDMARD use, n (%) | 15 (60) | 14 (56) | 1.000 |
| MTX use, n (%) | 16 (64) | 13 (52) | 0.567 |
| Glucocorticoid use, n (%) | 5 (20) | 6 (24) | 1.000 |
| RF positive, n (%) | 15 (60) | 18 (72) | 0.551 |
| CRP, mg/dL | 0.16 (0.03, 0.69) | 0.06 (0.04, 0.15) | 0.122 |
| DAS28-ESR | 2.68 (2.05, 3.52) | 2.75 (2.22, 3.5) | 0.769 |
| HAQ-DI | 0.25 (0, 1) | 0.375 (0, 0.5) | 0.902 |
| Cr-eGFR, mL/min/1.73m2 | 68.3 (57, 75.4) | 61.3 (20.275, 77.55) | 0.503 |
| Serum calcium level, mg/dL | 9.4 (9.2, 9.6) | 9.3 (9, 9.55) | 0.084 |
| Prior osteoporosis treatment, n (%) | 11 (44) | 13 (52) | 0.572 |
| Bisphosphonates, n (%) | 8 (32) | 9 (36) | |
| SERM, n (%) | 1 (4) | 1 (4) | |
| Active vitamin D3 analog, n (%) | 0 (0) | 3 (12) | |
| Oral calcium, n (%) | 2 (8) | 0 (0) | |
| Prevalent vertebral fractures, n (%) | 14 (56) | 14 (56) | 1.000 |
| T-score in lumbar spine | −2.1 (−2.9, −1.1) | −1.8 (−2.5, −1.1) | 0.560 |
| T-score in total hip | −1.9 (−2.9, −1.1) | −2.2 (−2.3, −1.8) | 0.814 |
| T-score in femoral neck | −3 (−3.4, −2.5) | −2.7 (−2.9, −2.3) | 0.047 |
| P1NP, ng/mL | 41.4 (25.7, 57) | 35.5 (21.1, 46.55) | 0.275 |
| TRACP-5b, mU/dL | 458 (302, 528) | 368 (263, 451) | 0.195 |
Q1, 25th percentile; Q3, 75th percentile; bDMARD, biological disease-modifying antirheumatic drug; MTX, methotrexate; RF, rheumatoid factor; CRP, C-reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; Cr-eGFR, estimated glomerular filtration rate calculated by creatinine; SERM, selective estrogen receptor modulator; P1NP, N-terminal propeptide of type I procollagen; TRACP-5b, tartrate-resistant acid phosphatase-5b.